muramidase and Plasmacytoma

Topics: Hexosaminidases; Humans; Isoenzymes; Karyotyping; Leukemia; Lymphocytes; Lymphoma; Lymphoproliferative Disorders; Muramidase; Nucleotidyltransferases; Plasmacytoma; Prognosis; Waldenstrom Macroglobulinemia

Topics: Amyloidosis; Blood Protein Disorders; Bone Neoplasms; gamma-Globulins; Humans; Karyotyping; Kidney Diseases; Kinetics; Leukemia; Leukemia, Lymphoid; Leukemia, Plasma Cell; Lung Neoplasms; Lymph Nodes; Lymphoma; Microscopy, Electron; Multiple Myeloma; Muramidase; Plasmacytoma

CD117 (c-Kit) and lysozyme are frequently expressed by myeloblasts and are sensitive markers for the diagnosis of extramedullary myeloid tumor. The diagnosis of cutaneous plasmacytoma presents a degree of difficulty, particularly with the plasmablastic variant, which can mimic hematologic as well as epithelioid malignancies. Approximately 25% of multiple myelomas express CD117 in the bone marrow by flow cytometry. Lysozyme immunoreactivity has been previously shown in 30% of poorly differentiated myelomas, while it is nonreactive in nonmalignant plasma cells.. To ascertain whether CD117 and lysozyme can aid in the diagnosis of cutaneous plasmacytomas, particularly the plasmablastic type.. Pathology reports of 2357 patients with a diagnosis of multiple myeloma were reviewed to find 13 cutaneous plasmacytomas (8 Bartl grade II, 5 Bartl grade III). Formalin-fixed, paraffin-embedded tissue sections were stained with CD117 and lysozyme on the Dako Autostainer system.Setting.-Patients with the diagnosis of multiple myeloma who developed cutaneous plasmacytoma(s).. The cutaneous plasmacytomas uniformly expressed CD117 in a cytoplasmic or membranous and cytoplasmic distribution with varying degrees of staining intensity unrelated to the Bartl grade of the lesion, while they were uniformly negative for lysozyme.. CD117 is a sensitive marker for malignant plasma cells in paraffin-embedded tissue, while lysozyme does not help identify poorly differentiated malignant plasma cells. While CD117 alone does not distinguish extramedullary myeloid tumor from poorly differentiated myeloma, the combination of CD117 and lysozyme may allow their differentiation. The possibility of c-kit inhibitors being used in the treatment of other hematopoietic malignancies allows speculation regarding implications for the treatment of multiple myeloma.

Topics: Biomarkers; Diagnosis, Differential; Humans; Immunohistochemistry; Muramidase; Plasmacytoma; Proto-Oncogene Proteins c-kit; Sarcoma, Myeloid; Skin Neoplasms

Recently, a reduction in the incidence of pristane-induced plasmacytomas in BALB/cAnPt (BALB/c) mice that were kept in viral specific pathogen-free (SPF) conditions has been reported. Environmentally, these SPF-BALB/c mice differed from conventionally-housed (CON) mice only in viral exposure and diet (i.e. sterilization of mouse chow), since microbial colonization of the intestinal tract was seen to be equivalent. This report assessed the ability of SPF- and CON-BALB/c mice to respond to immunologic challenge with soluble antigen, i.e. hen egg white lyzosyme (HEL), as a means of evaluating differences in T and B cell function and, indirectly, evaluating the possible effects these differences might have on plasmacytoma development. When cultured in vitro for 5 days with HEL, HEL-primed lymph node cells (LNC) from SPF-BALB/c mice proliferated to a significantly lesser extent than HEL-primed CON-BALB/c LNC. Moreover, HEL-induced production of IFN-gamma and IL-5 was significantly lower in SPF LNC. Serum IgG1 levels were 10-fold lower in SPF-BALB/c mice with, or without prior immunization with HEL and were not reconstituted by repeated injections of HEL in adjuvant. Serum IgM levels of SPF- and CON-BALB/c mice were equivalent. This reduction in immune responses could not be attributed to a lack of colonization of secondary lymphoid organs, since flow cytometric analysis of LNC revealed no difference in the number of recoverable cells and the proportion of lymphocyte subsets (CD4+, CD8+ and CD45+ cells) obtained from SPF- and CON-BALB/c mice. However, only CON LNC were induced to increase surface expression of CD44 after antigenic or mitogenic stimulation in vitro. Antibody responsiveness to HEL, as evidenced by serum anti-HEL binding or splenic hybridoma studies, demonstrated higher levels of IgG1 antibodies in CON BALB/c mice than in SPF mice. However, a greater proportion of the SPF IgG1 antibodies present were specifically directed against HEL, so that specific activity was greater in SPF-BALB/c mice. Therefore, while SPF BALB/c mice have a more restricted response to HEL than CON-BALB/c mice, those antibodies that are produced are more specifically directed against HEL with very little apparent bystander/polyclonal activation of multireactive cells. Resistance to plasmacytomas in SPF-BALB/c mice, therefore, may stem from a reduced number of circulating memory T and B cells, which are capable of reacting and/or crossreacting with a chronic inflammatory stim

Topics: Animals; Antigens; B-Lymphocytes; CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Chickens; Dose-Response Relationship, Immunologic; Epitopes; Female; Flow Cytometry; Fluorescent Antibody Technique, Direct; Freund's Adjuvant; Hyaluronan Receptors; Hybridomas; Immunocompetence; Immunoglobulin G; Immunoglobulin M; Interferon-gamma; Interleukin-5; Lymph Nodes; Lymphocyte Count; Lymphocyte Subsets; Male; Mice; Mice, Inbred BALB C; Muramidase; Plasmacytoma; Specific Pathogen-Free Organisms; T-Lymphocytes

Lysozyme, a hitherto myelomonocytic marker, has been previously reported as being raised in the sera of some myeloma patients. This fact, and the sporadical observation of a positive immunohistochemical lysozyme staining seen in some myelomas, prompted us to systematically search for an expression of lysozyme in both neoplastic and reactive plasma cells. A total of 74 paraffin-embedded, formalin-fixed, EDTA-decalcified core biopsies of newly diagnosed cases of plasmacytoma were immunohistochemically investigated for lysozyme expression by a modified avidin-biotin immunoperoxidase technique. The myelomas were subclassified according to their nuclear maturity into poorly differentiated plasmacytoma (PDP) (30 cases), moderately differentiated plasmacytoma (MDP) (24 cases), and well differentiated plasmacytoma (WDP) (20 cases). An unexpected lysozyme positivity was seen in 16/74 cases, and was most prevalent in 10/30 cases of PDP. No correlation has been detected between either lysozyme and kappa or lambda light chain expression, or an abnormal activity of chloroacetate esterase sometimes seen in myeloma. Since lysozyme has not been found in normal plasma cells or reactive plasmacytosis, the expression of this antigen in myeloma represents another example of so-called lineage infidelity, and parallels the previously reported abnormal expression of other myelomonocytic markers in some myelomas and a myeloma cell line. Apart from the unsettled prognostic impact, a facultative lysozyme expression in myeloma must be always considered when applying algorhythmic immunohistological strategies in delineating the histogenesis of haematopoietic or lymphatic malignancies.

Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Muramidase; Plasmacytoma; Staining and Labeling

ABL-MYC, a recombinant murine retrovirus that expresses v-abl and c-myc, rapidly induces transplantable mono- or oligoclonal plasmacytomas in BALB/c mice. To determine if the targets for transformation of this retrovirus are antigen-committed B lymphocytes and to explore this system as an alternative technique for producing antigen-specific monoclonal antibodies, plasmacytomas were induced in mice that had been immunized with two different types of immunogens, hen egg white lysozyme and sheep red blood cells. The majority of these plasmacytomas secreted immunogen-specific antibodies. Plasmacytomas induced in unimmunized mice did not react with hen egg white lysozyme or sheep red blood cells. The specific antibodies were comparable in concentration, specificity, and affinity to monoclonal antibodies obtained with conventional hybridoma technology, but, in addition to IgGs and IgMs, they included specific IgA antibodies, which are rare among splenic-derived hybridomas. Our results demonstrate that a principal target for ABL-MYC is an antigen-committed B lymphocyte. In addition this procedure provides an alternative method for the production of monoclonal antibodies, without a requirement for hetero-caryon formation by cell fusion techniques.

Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Blotting, Northern; Blotting, Southern; Gene Expression; Mice; Mice, Inbred BALB C; Muramidase; Oncogene Proteins v-abl; Oncogenes; Plasmacytoma; Proto-Oncogene Proteins c-myc; Proto-Oncogenes; Retroviridae; RNA, Messenger

Mouse inflammatory macrophages from C57BL/6N mice were fused with BALB/c mouse-derived myeloma cells (the CANS series). The hybrids in the early period after cell fusion (8 weeks) showed no macrophage functions (chemotaxis, EA and EAC rosette-forming abilities, phagocytosis or lysozyme production). EA rosette-forming ability was observed when these hybrids were treated with trypsin, whereas other macrophage functions were not. After prolonged culture, the hybrids (12 clones of 13 randomly selected) showed all the macrophage functions along with chromosome loss. Myeloma cell functions (kappa light chain production) were found in the young hybrids soon after cell fusion but were absent in the aged hybrids. These results indicated that reexpression of macrophage properties, except for EA rosette-forming abilities, takes place after the loss of chromosomes or genes repressing the expression of macrophage functions.

Topics: Animals; Cell Line; Chemotactic Factors; Chemotaxis; Hybrid Cells; Inflammation; Karyotyping; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muramidase; Plasmacytoma; Rosette Formation

Two cases of the development of acute myeloid leukemia (AML) after treatment with alkylating agents are reported. In Case 1, melphalan and then cyclophosphamide had been given for multiple myeloma. 46 months after onset of cytostatic treatment AML occurred, as confirmed cytochemically and by qualitative determination of urinary lysozyme. In Case 2, cyclophosphamide had been given for rheumatoid arthritis. After a latency of 34 months 'smouldering leukaemia' developed with an atypical monocytic leukaemic cell population. In a third case, multiple myeloma and monocytic leukaemia developed synchronously. The causative role of melphalan and cyclophosphamide in the development of AML seems securely established. Despite the risk of alkylating agents in the treatment of multiple myeloma or Hodgkin's disease causing AML, they should not be replaced, as other drugs have been shown to be less beneficial. On the other hand, alkylating agents should be used with great caution in the treatment of non-malignant diseases.

Topics: Aged; Alkylating Agents; Arthritis, Rheumatoid; Cyclophosphamide; Female; Humans; Immunoglobulin G; Leukemia, Monocytic, Acute; Male; Melphalan; Middle Aged; Muramidase; Plasmacytoma; Time Factors

Topics: Animals; Ascitic Fluid; Cell Line; DNA, Neoplasm; Humans; Karyotyping; Leukemia, Experimental; Leukemia, Myeloid; Male; Mice; Muramidase; Neoplasm Transplantation; Neoplasms, Multiple Primary; Paraffin; Plasmacytoma; Polyploidy